FDA approves COVID-19 treatment, alerts providers to unauthorized test
The Food and Drug Administration yesterday approved using Olumiant (baricitinib) to treat COVID-19 in hospitalized adults requiring supplemental oxygen, mechanical ventilation or extracorporeal membrane oxygenation (ECMO). The COVID-19 treatment was previously authorized for emergency use in hospitalized children and adults, and remains under EUA for hospitalized children.
In other news, FDA yesterday alerted health care providers and the public not to use the Skippack Medical Lab SARS-CoV-2 Antigen Rapid Test (Colloidal Gold) because the agency has not authorized or approved the test and it may produce false results.
Related News Articles
Headline
AHA's latest social media toolkit for encouraging vaccination against the flu and COVID-19 provides fall-themed social media posts and graphics. Download the…
Headline
The Centers for Disease Control and Prevention last week endorsed a recommendation for people aged 65 and older and for immunocompromised individuals to…
Headline
The Centers for Disease Control and Prevention is reminding clinicians and other health care workers to take necessary steps to keep themselves and their…
Chairperson's File
Autumn is here, and that means cooler weather and also the start of flu season.We know the best way to prevent influenza is to get a flu vaccine. The Centers…
Headline
The National Foundation for Infectious Diseases Sept. 25 released a survey showing that less than one in five U.S. adults are concerned about themselves or a…
Headline
The Food and Drug Administration Aug. 22 granted emergency use authorization for two new combined COVID-19 and influenza tests. The Nano-Check Influenza-COVID-…